GeneDx, a genetic diagnostics company, announced a 49% year-over-year revenue increase in Q2 2025, totaling $102.7 million and marking its fourth consecutive profitable quarter. Growth is primarily driven by whole-exome and whole-genome testing services, which accounted for 84% of the revenue and rose 69% compared to the previous year. The company reported gains in test volume and reimbursement rates, and plans to expand into the general pediatrics market following updated American Academy of Pediatrics guidelines endorsing genome sequencing. GeneDx also increased R&D spending and is positioning itself for long-term growth in genomic medicine.